Compugen to Participate in the JMP Securities C-Suite Series- TIGIT Landscape Overview
Compugen Ltd. (NASDAQ: CGEN) announced its participation in the JMP Securities C-Suite Series, scheduled for January 30, 2023, at 11:00 am ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Compugen Ltd. (NASDAQ: CGEN) announced its participation in the JMP Securities C-Suite Series, scheduled for January 30, 2023, at 11:00 am ET. CEO Anat Cohen-Dayag and other management team members will discuss the company's advancements in the DNAM-1 axis. A live webcast of the event will be available on Compugen's Investor Relations webpage, with a replay accessible afterward. Compugen specializes in cancer immunotherapies and has developed several promising product candidates, including COM701 and COM902 for solid tumors, with ongoing collaborations such as the AZD2936 program with AstraZeneca.
Details
News Market Reaction – CGEN
The recorded move for CGEN in the trading session of this news was -0.15%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
A live webcast will be accessible on the Investor Relations section of the
About Compugen
Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has developed two proprietary product candidates: COM701, a potential first-in-class anti-PVRIG antibody and COM902, a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors. Partnered programs include a PD-1/TIGIT bispecific derived from COM902 (AZD2936) in Phase 2 development by AstraZeneca through a license agreement for the development of bispecific and multi-specific antibodies. In addition, the Company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets. The most advanced program, COM503 is about to enter pre-IND enabling studies. COM503 is a potential first-in-class, high affinity antibody targeting cytokine biology to enhance anti-tumor immunity in a differentiated manner. Compugen is headquartered in
Company contact:
Head of Investor Relations and Corporate Communications
Email: ir@cgen.com
Tel: +1 (628) 241-0071
View original content:https://www.prnewswire.com/news-releases/compugen-to-participate-in-the-jmp-securities-c-suite-series--tigit-landscape-overview-301727997.html
SOURCE
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.